FGEN.O
Latest Trade
10.92USDChange
0.06(+0.55%)Volume
120,283Today's Range
-
11.0552 Week Range
-
57.21As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 10.86 |
|---|---|
Open | 10.86 |
Volume | 120,283 |
3M AVG Volume | 26.05 |
Today's High | 11.05 |
Today's Low | 10.83 |
52 Week High | 57.21 |
52 Week Low | 9.88 |
Shares Out (MIL) | 92.62 |
Market Cap (MIL) | 1,005.87 |
Forward P/E | -3.90 |
Dividend (Yield %) | -- |
Astellas Receives European Commission Approval For First-In-Class Evrenzo (Roxadustat) For Adult Patients With Symptomatic Anemia Of Chronic Kidney Disease
Fibrogen Announces Retirement Of Pat Cotroneo And Appointment Of Juan Graham As CFO
FibroGen Receives Complete Response Letter From The FDA For Roxadustat For Anemia Of Chronic Kidney Disease
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase (HIF-PH) activity for the treatment of anemia caused by chronic kidney disease (CKD). It is also developing Roxadustat for anemia associated with myelodysplastic syndromes (MDS). The Company is also developing Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD).
Industry
Business Services
Contact Info
409 Illinois St
SAN FRANCISCO, CA
94158-2509
United States
+1.415.9781200
http://www.fibrogen.comExecutive Leadership
James A. Schoeneck
Chairman of the Board
Enrique A. Conterno
Chief Executive Officer, Director
Juan Graham
Chief Financial Officer
Christine L. Chung
Senior Vice President, China Operations
Elias Kouchakji
Senior Vice President, Clinical Development, Drug Safety and Pharmacovigilance
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 5.85 |
Price To Book (MRQ) | 3.86 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 7.03 |
LT Debt To Equity (MRQ) | 7.02 |
Return on Investment (TTM) | -36.56 |
Return on Equity (TTM) | -28.67 |
FibroGen Inc said said on Wednesday that the U.S. Food and Drug Administration has declined to approve its treatment for anemia of chronic kidney disease, citing the need for an additional clinical study.
* FIBROGEN - ON JULY 8, UNITS AND ASTRAZENECA ENTERED INTO AN AMENDMENT TO AMENDED AND RESTATED LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
* FIBROGEN ANNOUNCES FIRST PATIENT ENROLLED IN PAMREVLUMAB CLINICAL TRIAL IN PATIENTS HOSPITALIZED IN U.S. WITH ACUTE COVID-19
* FIBROGEN ANNOUNCES NEW ROXADUSTAT DATA PRESENTED AT 2020 ERA-EDTA VIRTUAL CONGRESS
* FIBROGEN ANNOUNCES FIRST PATIENT ENROLLED IN PAMREVLUMAB CLINICAL TRIAL IN PATIENTS HOSPITALIZED IN ITALY WITH SEVERE COVID-19 Source text for Eikon: Further company coverage:
* FIBROGEN - UK HIGH COURT OF JUSTICE HAS HELD CERTAIN PATENTS RELATING TO METHODS OF USING HIF-PHIS TO BE INVALID
* FIBROGEN INC - AGREEMENT WITH SHANGHAI SYNTHEALL PHARMACEUTICAL CO LTD, STA PHARMACEUTICAL HONG KONG LIMITED FOR BULK MANUFACTURE/SUPPLY OF ROXADUSTAT
China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.